A
Affect Therapeutics
Using mobile technology to deliver the world's first evidence-based, substance-specific recovery program for methamphetamine and cocaine use disorder
About Affect Therapeutics
Affect Therapeutics is a digital healthcare startup that operates in the addiction recovery sector. The company offers a unique, science-based approach to addiction treatment, using a combination of financial incentives, therapy, and medication to help individuals overcome their addictions. This approach, known as "contingency management," rewards healthy behaviors and encourages the formation of new habits, leading to better recovery outcomes.
Affect Therapeutics serves individuals struggling with addiction, providing them with a private, fully digital, and always accessible platform for treatment. All appointments are conducted via secure video conference, eliminating the need for physical travel to a rehab clinic. This convenience and privacy make the service appealing to those who may be hesitant to seek help in traditional settings.
In addition to treatment, Affect Therapeutics also offers support in other areas of life that can impact recovery, such as job hunting, finding a better place to live, or managing bills. This holistic approach recognizes that getting sober is not just about quitting substances, but also about improving one's overall life circumstances.
The company's business model is likely based on a subscription or fee-for-service model, where clients pay for the treatment and support services they receive. This revenue is then used to fund the company's operations and growth.
In summary, Affect Therapeutics is a digital healthcare startup that provides a comprehensive, science-based, and convenient approach to addiction recovery, helping individuals not only overcome their addictions but also improve their overall life circumstances.
Source: Dealroom company dataKnowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Nov 2025 | $26M | $104M | City Light Capital · LifeArc Ventures · AlleyCorp · Allumia Ventures | ↗ |
| SERIES A✓Equity / VC | Jul 2023 | $16M | $64M | City Light Capital · What If Ventures · LifeArc Ventures · Samsung Next | ↗ |
Growth signals
Latest recorded traffic for Affect Therapeutics is 56K monthly website visits, up 80.6% over the last three months. Affect Therapeutics's team grew 27.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
AlleyCorp
Kapor Capital
City Light Capital
Acumen
Series A5 investors entered at this stage
What If Ventures
Artis Ventures
LifeArc Ventures
Samsung Next
Allumia Ventures
Other known investors2 additional known investors
Mana Ventures
Small Business Innovation Research
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Affect Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Affect Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







